瑞格列奈、甘精胰岛素治疗2型糖尿病的临床疗效

Clinical Efficacy of Repaglinide Plus Insulin Glargine in Treating Type 2 Diabetes Mellitus

目的研究瑞格列奈联合甘精胰岛素治疗2型糖尿病的临床疗效及安全性观察。方法选择医院2018年1月—2020年1月收入的80例2型糖尿病,按照随机数字表法分为两组,均40例,其中对照组实施甘精胰岛素治疗,研究组在此基础上实施瑞格列奈,分析两组血糖、胰岛素水平。结果治疗前两组血糖、胰岛素情况差异无统计学意义(P>0.05),治疗后研究组血糖均低于对照组,胰岛素水平均高于对照组,差异有统计学意义(P<0.05)。结论对于2型糖尿病可采取瑞格列奈联合甘精胰岛素治疗,可改善患者血糖情况,提升胰岛功能。

Objective To study the efficacy and safety of repaglinide plus insulin glargine in treating type 2 diabetes mellitus(T2DM).Methods 80 T2DM patients treated from January 2018 to January 2020 in our hospital were selected and assigned to two groups according to random number table,40 cases in each group.The control group was taken insulin glargine,the research group was taken insulin glargine and repaglinide.Blood glucose and pancreatic function indicators of two groups were studied.Results Before treatment,there was no significant difference in blood glucose and pancreatic islets between the two groups(P>0.05).After treatment,the blood glucose of the study group was lower than that of the control group,and the insulin level was higher than that of the control group.The difference was statistically significant(P<0.05).Conclusion Repaglinide combined with insulin glargine can efficiently improve the blood glucose and pancreatic function of type 2 diabetes mellitus patients.